Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice.
Nanoparticles have been extensively developed for therapeutic and diagnostic applications. While the focus of nanoparticle trafficking in vivo has traditionally been on drug delivery and organ-level biodistribution and clearance, recent work in cancer biology and infectious disease suggests that tar...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/935c5712198046a0a5ed79003caccaa8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:935c5712198046a0a5ed79003caccaa8 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:935c5712198046a0a5ed79003caccaa82021-11-18T07:48:26ZPeripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice.1932-620310.1371/journal.pone.0061646https://doaj.org/article/935c5712198046a0a5ed79003caccaa82013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23626707/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Nanoparticles have been extensively developed for therapeutic and diagnostic applications. While the focus of nanoparticle trafficking in vivo has traditionally been on drug delivery and organ-level biodistribution and clearance, recent work in cancer biology and infectious disease suggests that targeting different cells within a given organ can substantially affect the quality of the immunological response. Here, we examine the cell-level biodistribution kinetics after administering ultrasmall Pluronic-stabilized poly(propylene sulfide) nanoparticles in the mouse. These nanoparticles depend on lymphatic drainage to reach the lymph nodes and blood, and then enter the spleen rather than the liver, where they interact with monocytes, macrophages and myeloid dendritic cells. They were more readily taken up into lymphatics after intradermal (i.d.) compared to intramuscular administration, leading to ∼50% increased bioavailability in blood. When administered i.d., their distribution favored antigen-presenting cells, with especially strong targeting to myeloid cells. In tumor-bearing mice, the monocytic and the polymorphonuclear myeloid-derived suppressor cell compartments were efficiently and preferentially targeted, rendering this nanoparticulate formulation potentially useful for reversing the highly suppressive activity of these cells in the tumor stroma.Iraklis C KourtisSachiko HirosueAlexandre de TittaStephan KontosToon StegmannJeffrey A HubbellMelody A SwartzPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 4, p e61646 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Iraklis C Kourtis Sachiko Hirosue Alexandre de Titta Stephan Kontos Toon Stegmann Jeffrey A Hubbell Melody A Swartz Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. |
| description |
Nanoparticles have been extensively developed for therapeutic and diagnostic applications. While the focus of nanoparticle trafficking in vivo has traditionally been on drug delivery and organ-level biodistribution and clearance, recent work in cancer biology and infectious disease suggests that targeting different cells within a given organ can substantially affect the quality of the immunological response. Here, we examine the cell-level biodistribution kinetics after administering ultrasmall Pluronic-stabilized poly(propylene sulfide) nanoparticles in the mouse. These nanoparticles depend on lymphatic drainage to reach the lymph nodes and blood, and then enter the spleen rather than the liver, where they interact with monocytes, macrophages and myeloid dendritic cells. They were more readily taken up into lymphatics after intradermal (i.d.) compared to intramuscular administration, leading to ∼50% increased bioavailability in blood. When administered i.d., their distribution favored antigen-presenting cells, with especially strong targeting to myeloid cells. In tumor-bearing mice, the monocytic and the polymorphonuclear myeloid-derived suppressor cell compartments were efficiently and preferentially targeted, rendering this nanoparticulate formulation potentially useful for reversing the highly suppressive activity of these cells in the tumor stroma. |
| format |
article |
| author |
Iraklis C Kourtis Sachiko Hirosue Alexandre de Titta Stephan Kontos Toon Stegmann Jeffrey A Hubbell Melody A Swartz |
| author_facet |
Iraklis C Kourtis Sachiko Hirosue Alexandre de Titta Stephan Kontos Toon Stegmann Jeffrey A Hubbell Melody A Swartz |
| author_sort |
Iraklis C Kourtis |
| title |
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. |
| title_short |
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. |
| title_full |
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. |
| title_fullStr |
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. |
| title_full_unstemmed |
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. |
| title_sort |
peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/935c5712198046a0a5ed79003caccaa8 |
| work_keys_str_mv |
AT iraklisckourtis peripherallyadministerednanoparticlestargetmonocyticmyeloidcellssecondarylymphoidorgansandtumorsinmice AT sachikohirosue peripherallyadministerednanoparticlestargetmonocyticmyeloidcellssecondarylymphoidorgansandtumorsinmice AT alexandredetitta peripherallyadministerednanoparticlestargetmonocyticmyeloidcellssecondarylymphoidorgansandtumorsinmice AT stephankontos peripherallyadministerednanoparticlestargetmonocyticmyeloidcellssecondarylymphoidorgansandtumorsinmice AT toonstegmann peripherallyadministerednanoparticlestargetmonocyticmyeloidcellssecondarylymphoidorgansandtumorsinmice AT jeffreyahubbell peripherallyadministerednanoparticlestargetmonocyticmyeloidcellssecondarylymphoidorgansandtumorsinmice AT melodyaswartz peripherallyadministerednanoparticlestargetmonocyticmyeloidcellssecondarylymphoidorgansandtumorsinmice |
| _version_ |
1718422924898074624 |